Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the
Event Scheduled for Tuesday, September 29 at 8:00 a.m. ET
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat
SANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady,
New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) between November 3, 2023 and
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Shareholders who purchased shares of ALDX during the class period
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) between November 3, 2023 and March 16,
New York, New York--(Newsfile Corp. - May 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) between November 3, 2023 and
ATLANTA, May 27, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ:ALDX). The lawsuit alleges that Defendants issued false and misleading
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options If you purchased or acquired
